共 50 条
[1]
Siu YP(2006)Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level Am J Kidney Dis 47 51-59
[2]
Leung KT(2017)2016 Updated EULAR evidence-based recommendations for the management of gout Ann Rheum Dis 76 29-42
[3]
Tong MK(2012)Decreased extra-renal urate excretion is a common cause of hyperuricemia Nat Commun 3 764-29
[4]
Richette P(2018)The use survey of antihyperuricemic in clinicians Gout Nucleic Acid Metab 42 23-S34
[5]
Doherty M(2011)A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study J Clin Rheumatol 17 S27-1389
[6]
Pascual E(2011)Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors J Rheumatol 38 1385-783
[7]
Ichida K(2015)Effects of febuxostat on serum urate level in Japanese hyperuricemia patients Mod Rheumatol 25 779-1210
[8]
Matsuo H(2018)cardiovascular safety of febuxostat or allopurinol in patients with gout N Engl J Med 29 1200-1786
[9]
Takada T(2019)Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy Eur Heart J 7 1778-379
[10]
Hosoya T(1994)Hepatic injury caused by benzbromarone J Hepatol 20 376-971